Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

A functional radioreceptor assay of alpha-V-beta-3 (alphavbeta3) inhibitors in plasma: application as an ex vivo pharmacodynamic model.

Chaikin MA, Marugan JJ, De Vries GW, Baciu P, Edelman J, Ni M, Tomczuk BE, Pan W, Guo Z, Anaclerio B, Leonard K, Eisennagel SH, Molloy CJ, Manthey CL.

J Biochem Biophys Methods. 2005 Dec 31;65(2-3):107-20. Epub 2005 Nov 21.

PMID:
16325916
2.

Discovery of small molecule inhibitors of integrin alphavbeta3 through structure-based virtual screening.

Zhou Y, Peng H, Ji Q, Qi J, Zhu Z, Yang C.

Bioorg Med Chem Lett. 2006 Nov 15;16(22):5878-82. Epub 2006 Sep 18.

PMID:
16982193
3.

[Design and activity determination of small molecular inhibitors of integrin alphavbeta3].

Ji Q, Zhou Y, Peng H, Huang N, Qi J, Xiong DS, Gao YD, Yang M, Yang CZ.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2007 Jun;29(3):347-52. Chinese.

4.

Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis.

Kumar CC.

Curr Drug Targets. 2003 Feb;4(2):123-31. Review.

PMID:
12558065
5.

Disposition of a novel and potent alpha(v)beta3 antagonist in animals, and extrapolation to man.

Prueksaritanont T, Fernandez-Metzler C, Meng Y, Barrish A, Halczenko W, Rodan SB, Hutchinson JH, Duggan ME, Lin JH.

Xenobiotica. 2004 Jan;34(1):103-15.

PMID:
14742139
6.

Use of antibody as carrier of oligomers of peptidomimetic alphavbeta3 antagonist to target tumor-induced neovasculature.

Shin IS, Jang BS, Danthi SN, Xie J, Yu S, Le N, Maeng JS, Hwang IS, Li KC, Carrasquillo JA, Paik CH.

Bioconjug Chem. 2007 May-Jun;18(3):821-8. Epub 2007 Mar 22.

PMID:
17375899
7.

Angiogenesis inhibition and choroidal neovascularization suppression by sustained delivery of an integrin antagonist, EMD478761.

Fu Y, Ponce ML, Thill M, Yuan P, Wang NS, Csaky KG.

Invest Ophthalmol Vis Sci. 2007 Nov;48(11):5184-90.

PMID:
17962472
8.

Abrogation of the interaction between osteopontin and alphavbeta3 integrin reduces tumor growth of human lung cancer cells in mice.

Cui R, Takahashi F, Ohashi R, Gu T, Yoshioka M, Nishio K, Ohe Y, Tominaga S, Takagi Y, Sasaki S, Fukuchi Y, Takahashi K.

Lung Cancer. 2007 Sep;57(3):302-10. Epub 2007 May 4.

PMID:
17482311
9.

Discovery of small molecule integrin alphavbeta3 antagonists as novel anticancer agents.

Dayam R, Aiello F, Deng J, Wu Y, Garofalo A, Chen X, Neamati N.

J Med Chem. 2006 Jul 27;49(15):4526-34.

PMID:
16854058
10.

alphavbeta3 integrin and angiogenesis: a moody integrin in a changing environment.

Hodivala-Dilke K.

Curr Opin Cell Biol. 2008 Oct;20(5):514-9. doi: 10.1016/j.ceb.2008.06.007. Epub 2008 Aug 6. Review.

PMID:
18638550
11.

SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity.

Wilkinson-Berka JL, Jones D, Taylor G, Jaworski K, Kelly DJ, Ludbrook SB, Willette RN, Kumar S, Gilbert RE.

Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1600-5.

PMID:
16565398
12.

Ligands for mapping alphavbeta3-integrin expression in vivo.

Schottelius M, Laufer B, Kessler H, Wester HJ.

Acc Chem Res. 2009 Jul 21;42(7):969-80. doi: 10.1021/ar800243b.

PMID:
19489579
13.

Determination of the benzodiazepine plasma concentrations in suicidal patients using a radioreceptor assay.

de Jong LA, Verwey B, Essink G, Muntendam A, Zitman FG, Ensing K.

J Anal Toxicol. 2004 Oct;28(7):587-92.

14.

Discovery of +(2-{4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl}-cyclopropyl)acetic acid as potent and selective alphavbeta3 inhibitor: design, synthesis, and optimization.

Nagarajan SR, Lu HF, Gasiecki AF, Khanna IK, Parikh MD, Desai BN, Rogers TE, Clare M, Chen BB, Russell MA, Keene JL, Duffin T, Engleman VW, Finn MB, Freeman SK, Klover JA, Nickols GA, Nickols MA, Shannon KE, Steininger CA, Westlin WF, Westlin MM, Williams ML.

Bioorg Med Chem. 2007 May 15;15(10):3390-412. Epub 2007 Mar 13.

PMID:
17387018
15.

Integrin alpha3beta1, a novel receptor for alpha3(IV) noncollagenous domain and a trans-dominant Inhibitor for integrin alphavbeta3.

Borza CM, Pozzi A, Borza DB, Pedchenko V, Hellmark T, Hudson BG, Zent R.

J Biol Chem. 2006 Jul 28;281(30):20932-9. Epub 2006 May 26.

16.

Novel inhibitors of the alphavbeta3 integrin--lead identification strategy.

Elliot D, Henshaw E, MacFaul PA, Morley AD, Newham P, Oldham K, Page K, Rankine N, Sharpe P, Ting A, Wood CM.

Bioorg Med Chem Lett. 2009 Aug 15;19(16):4832-5. doi: 10.1016/j.bmcl.2009.06.041. Epub 2009 Jun 13.

PMID:
19574045
17.

Inhibition of angiogenesis by interleukin-4 gene therapy in rat adjuvant-induced arthritis.

Haas CS, Amin MA, Allen BB, Ruth JH, Haines GK 3rd, Woods JM, Koch AE.

Arthritis Rheum. 2006 Aug;54(8):2402-14.

18.
19.

A novel alpha(v)beta (3)-blocking disintegrin containing the RGD motive, DisBa-01, inhibits bFGF-induced angiogenesis and melanoma metastasis.

Ramos OH, Kauskot A, Cominetti MR, Bechyne I, Salla Pontes CL, Chareyre F, Manent J, Vassy R, Giovannini M, Legrand C, Selistre-de-Araujo HS, Crépin M, Bonnefoy A.

Clin Exp Metastasis. 2008;25(1):53-64. Epub 2007 Oct 19.

PMID:
17952617
20.

Effects of a monoclonal anti-alphavbeta3 integrin antibody on blood vessels - a pharmacodynamic study.

Zhang D, Pier T, McNeel DG, Wilding G, Friedl A.

Invest New Drugs. 2007 Feb;25(1):49-55. Epub 2006 Sep 26.

PMID:
17001523
Items per page

Supplemental Content

Write to the Help Desk